SCHEMBL247791

SCHEMBL247791

CN(C)CCCCC(=O)O

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4A O75164 12/20 0.64
KDM4C Q9H3R0 12/20 0.64
KDM5A P29375 1/20 0.64
KDM7A Q6ZMT4 1/20 0.64
PHF8 Q9UPP1 1/20 0.64
KDM2A Q9Y2K7 1/20 0.64
LMNA P02545 2/20 0.58
TSHR P16473 2/20 0.55
NFKB1 P19838 1/20 0.55
PMP22 Q01453 1/20 0.55
AKR1B1 P15121 1/20 0.52
FOLH1 Q04609 1/20 0.52
GPR84 Q9NQS5 2/20 0.50
PPARG P37231 2/20 0.50
PPARD Q03181 2/20 0.50
PPARA Q07869 2/20 0.50
ALDH1A1 P00352 1/20 0.50
SLC22A6 Q4U2R8 1/20 0.50
SLC22A8 Q8TCC7 1/20 0.50
TLR2 O60603 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6647561 0.97 KDM4A (0.66) KDM4AKDM4CKDM5AKDM7APHF8
SCHEMBL6029256 0.97 KDM4A (0.68) KDM4AKDM4CKDM5AKDM7APHF8
SCHEMBL1176587 0.97 KDM4A (0.68) KDM4AKDM4CKDM5AKDM7APHF8
SCHEMBL219327 0.97 KDM4A (0.68) KDM4AKDM4CKDM5AKDM7APHF8
SCHEMBL3402761 0.97 KDM4A (0.68) KDM4AKDM4CKDM5AKDM7APHF8
SCHEMBL5530872 0.97 KDM4A (0.68) KDM4AKDM4CKDM5AKDM7APHF8
SCHEMBL5219324 0.97 KDM4A (0.68) KDM4AKDM4CKDM5AKDM7APHF8
SCHEMBL13286331 0.97 KDM4A (0.68) KDM4AKDM4CKDM5AKDM7APHF8
SCHEMBL8213501 0.97 KDM4A (0.68) KDM4AKDM4CKDM5AKDM7APHF8
SCHEMBL28020165 0.97 KDM4A (0.68) KDM4AKDM4CKDM5AKDM7APHF8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 370 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025080945-A1 LIPID NANOPARTICLES CodeBridgeBio Inc. (US) 2025-04-17 WO claimed
CN-119233657-A Perovskite solar cell, preparation method thereof and photovoltaic module 天合光能股份有限公司 2024-12-31 CN claimed
WO-2024197404-A1 BACTERIA-RESPONSIVE PARTICLES, METHODS FOR PREPARATION, AND USE IN PACKAGING OR ON SURFACES HO EMMANUEL ABRAHAM (CA) 2024-10-03 WO claimed
CN-112707670-B Cross-linked concrete viscosity regulator and preparation method thereof 科之杰新材料集团有限公司 2022-04-22 CN claimed
CN-107208095-B Compositions and methods for silencing hepatitis b virus gene expression 阿布特斯生物制药公司 2021-11-16 CN claimed
EP-3201338-B1 COMPOSITIONS AND METHODS FOR SILENCING HEPATITIS B VIRUS GENE EXPRESSION ARBUTUS BIOPHARMA CORP (CA) 2021-11-03 EP claimed
CN-112745459-A Concrete viscosity regulator and preparation method thereof 科之杰新材料集团有限公司 2021-05-04 CN claimed
CN-112707670-A Cross-linked concrete viscosity regulator and preparation method thereof 科之杰新材料集团有限公司 2021-04-27 CN claimed
EP-3558271-A1 METHODS FOR AMELIORATING INFUSION REACTIONS Arbutus Biopharma Corporation (CA) 2019-10-30 EP claimed
EP-3500294-A1 ANTI-PD-1 ANTIBODIES, OR FRAGMENTS THEREOF, FOR TREATING HEPATITIS B Arbutus Biopharma Corporation (CA) 2019-06-26 EP claimed
WO-2018119115-A1 METHODS FOR AMELIORATING INFUSION REACTIONS PROTIVA BIOTHERAPEUTICS, INC. (CA) 2018-06-28 WO claimed
WO-2018039131-A1 ANTI-PD-1 ANTIBODIES, OR FRAGMENTS THEREOF, FOR TREATING HEPATITIS B PROTIVA BIOTHERAPEUTICS, INC. (CA) 2018-03-01 WO claimed
CN-107208095-A Composition and method for making hepatitis B virogene expression silencing 普洛体维生物治疗公司 2017-09-26 CN claimed
EP-2828257-B1 ANTIBACTERIAL COMPOUNDS BIOTA EUROPE LTD (GB) 2017-07-26 EP claimed
EP-3033325-A1 COMPOSITIONS AND METHODS FOR DELIVERING MESSENGER RNA Protiva Biotherapeutics, Inc. (CA) 2016-06-22 EP claimed
US-9365508-B2 Aroyl thiourea derivatives UNIVERSITY COURT OF THE UNIVERSITY OF ST ANDREWS (GB) 2016-06-14 US claimed
WO-2015011633-A1 COMPOSITIONS AND METHODS FOR DELIVERING MESSENGER RNA PROTIVA BIOTHERAPEUTICS, INC. (CA) 2015-01-29 WO claimed
EP-1312616-B1 Preparation of compounds of the kind polysaccharide betainates, obtained compounds, their use and the compositions containing them OREAL (FR) 2008-01-23 EP claimed
US-20070160557-A1 Preparation of polysaccharide betainate type compounds, compounds obtained, their use and compositions comprising them L'OREAL S.A. 2007-07-12 US claimed
US-20030147818-A1 Preparation of polysaccharide betainate type compounds, compounds obtained, their use and compositions comprising them L'OREAL S.A. (FR) 2003-08-07 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070160557-A1 Preparation of polysaccharide betainate type compounds, compounds obtained, their use and compositions comprising them ALG1, MANBA, FUT5 KDM4A 3132/4885KDM4C 1078/4885KDM5A 2052/4885
US-20030147818-A1 Preparation of polysaccharide betainate type compounds, compounds obtained, their use and compositions comprising them ALG1, MANBA, FUT5 KDM4A 3182/4885KDM4C 1119/4885KDM5A 2206/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.